23 May 2013
Keywords: Novo Nordisk, BLA, USA, Congenital factro XIII, FXIII, Bleeding disorder
Article | 24 February 2011
The US unit of Danish insulin giant Novo Nordisk (NVO: N) has submitted a Biologic License Application (BLA) to the ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
24 February 2011
© 2013 thepharmaletter.com